var data={"title":"Diclofenac (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diclofenac (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388154?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diclofenac-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diclofenac (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=diclofenac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diclofenac (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016815\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious cardiovascular thrombotic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious gastrointestinal bleeding, ulceration, and perforation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016831\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cambia;</li>\n      <li>Cataflam [DSC];</li>\n      <li>Dyloject [DSC];</li>\n      <li>Voltaren-XR [DSC];</li>\n      <li>Zipsor;</li>\n      <li>Zorvolex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016832\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Diclo;</li>\n      <li>Apo-Diclo Rapide;</li>\n      <li>Apo-Diclo SR;</li>\n      <li>Cambia;</li>\n      <li>Diclofenac EC;</li>\n      <li>Diclofenac ECT;</li>\n      <li>Diclofenac K;</li>\n      <li>Diclofenac-SR;</li>\n      <li>Dom-Diclofenac;</li>\n      <li>Dom-Diclofenac SR;</li>\n      <li>PMS-Diclofenac;</li>\n      <li>PMS-Diclofenac K;</li>\n      <li>PMS-Diclofenac-SR;</li>\n      <li>PRO-Diclo-Rapide;</li>\n      <li>Sandoz-Diclofenac;</li>\n      <li>Sandoz-Diclofenac Rapide;</li>\n      <li>Sandoz-Diclofenac SR;</li>\n      <li>Teva-Diclofenac;</li>\n      <li>Teva-Diclofenac EC;</li>\n      <li>Teva-Diclofenac K;</li>\n      <li>Teva-Diclofenac SR;</li>\n      <li>Voltaren;</li>\n      <li>Voltaren Rapide;</li>\n      <li>Voltaren SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017469\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Nonopioid;</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID);</li>\n      <li>\n        Nonsteroidal Anti-inflammatory Drug (NSAID), Oral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017009\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> For all indications, it has been recommended to not exceed 100 mg/day based on increased risk of vascular events (eg, stroke, non-fatal MI) (Bhala 2013; Health Canada communication 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis:</b> Oral: Delayed-release tablet: 25 mg 4 times daily and 25 mg at bedtime as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine:</b> Oral: Powder for oral solution: 50 mg (one packet) as a single dose; safety and efficacy of a second dose have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release tablet: 50 mg 2 to 3 times daily; Delayed-release tablet: 50 mg 2 to 3 times daily or 75 mg twice daily; Extended-release tablet: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release capsule: Zorvolex (diclofenac acid): 35 mg 3 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal suppository [Canadian product]: Insert 50 mg or 100 mg rectally as single dose to substitute for final oral daily dose (maximum combined dose [rectal and oral]: 100 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release tablet: 50 mg 3 times daily; may administer 100 mg as an initial dose, followed by 50 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Zipsor (diclofenac potassium): 25 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Zorvolex (diclofenac acid): 18 mg or 35 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 37.5 mg every 6 hours as needed; adjust frequency according to patient response (maximum: 150 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary dysmenorrhea:</b> Oral: Immediate-release tablet: 50 mg 3 times daily; may administer 100 mg as an initial dose, followed by 50 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Immediate-release tablet: 50 mg 3 to 4 times daily; Delayed-release tablet: 50 mg 3 to 4 times daily or 75 mg twice daily; Extended-release tablet: 100 mg once daily; may increase to 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal suppository [Canadian product]: Insert 50 mg or 100 mg rectally as single dose to substitute for final oral daily dose (maximum combined dose [rectal and oral]: 100 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26620531\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=diclofenac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diclofenac (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Juvenile idiopathic arthritis (off-label use):</b> Children &ge;3 years and Adolescents: Oral: Delayed-release tablet (diclofenac sodium): 2 to 3 mg/kg/day in divided doses (Haapasaari, 1983; Hashkes, 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017010\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; initiate using lowest recommended dose and frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017011\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Significant impairment or advanced renal disease: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Moderate to severe impairment: Use is not recommended; contraindicated in patients in the perioperative period and who are at risk for volume depletion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">KDIGO 2012 guidelines provide the following recommendations for NSAIDs:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR 30 to &lt;60 mL/minute/1.73 m<sup>2</sup>: Temporarily discontinue in patients with intercurrent disease that increases risk of acute kidney injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017012\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, may require dosage adjustment due to extensive hepatic metabolism. Additional product-specific recommendations: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cambia: Use the lowest effective dose for the shortest duration possible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zipsor/Zorvolex: Initial: Initiate treatment at the lowest dose; if efficacy is not achieved with the lowest dose, discontinue use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Moderate to severe impairment: Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017239\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as base: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zorvolex: 18 mg, 35 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zipsor: 25 mg [contains gelatin (bovine)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cambia: 50 mg (1 ea, 9 ea) [anise-mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cambia: 50 mg (1 ea [DSC], 9 ea [DSC]) [contains aspartame, saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cambia: 50 mg (1 ea [DSC], 9 ea [DSC]) [contains aspartame, saccharin sodium; anise-mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dyloject: 37.5 mg/mL (1 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as potassium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cataflam: 50 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Voltaren-XR: 100 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016834\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11590267\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren: 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral, as potassium:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren Rapide: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016830\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Cambia: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022165s012lbl.pdf#page=19&amp;token=gqGA+tNiB3KjtHPVpLZXl8NjSKFVA2ddJsOYsSpQFnIaNVhH9V1UpljACpnleXskq5P371LluKs+nJInPa8oxLu9c9DXKv+wB7EZIFpy/Hdc3MSgSVyoTmpSsjvszMBn&amp;TOPIC_ID=9103\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022165s012lbl.pdf#page=19</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Cataflam: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQBz/6eI3T1nzb0/4YCYZ53Q==&amp;TOPIC_ID=9103\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135935.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">NSAID: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WJqYrx1xLSb8GxuJFaqJ8Kg==&amp;TOPIC_ID=9103\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM387559.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Voltaren-XR: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlXy07xMqYjc5Z/G5Gnd69Bw==&amp;TOPIC_ID=9103\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089822.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Zipsor: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243355.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68ioHaLrrKK1t0e0G3ohHD6w==&amp;TOPIC_ID=9103\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM243355.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Zorvolex: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM372061.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WKDuGUqLxcIxpzfv124Aahg==&amp;TOPIC_ID=9103\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM372061.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017044\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Administer as an IV bolus over 15 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Do not crush delayed- or extended-release tablets. May administer immediate-release formulations with food or milk to avoid gastric distress.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cambia, Zorvolex: Administering with food may cause a reduction in effectiveness.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016835\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ankylosing spondylitis (delayed-release tablets only):</b> Acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dysmenorrhea (immediate-release tablets only):</b> Treatment of primary dysmenorrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine (powder for oral solution only):</b> Acute treatment of migraine attacks with or without aura in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoarthritis (immediate-release, extended-release, and delayed-release tablets; capsules [Zorvolex]; and suppositories [Canadian product] only):</b> Relief of signs and symptoms of osteoarthritis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Capsules/immediate-release tablets only:</b> Relief of mild to moderate acute pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Injection only:</b> Management of mild to moderate pain and moderate to severe pain (alone or in combination with opioid analgesics) in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis (immediate-release, extended-release, and delayed-release tablets; and suppositories [Canadian product] only):</b> Relief of signs and symptoms of rheumatoid arthritis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725523\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Juvenile idiopathic arthritis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016829\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diclofenac may be confused with Diflucan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cataflam may be confused with Catapres</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Voltaren may be confused with traMADol, Ultram, Verelan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Diclofenac is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent) due to increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, older than 75 years of age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents). May increase risk of acute kidney injury and further decline of kidney function in elderly patients with stages IV or higher chronic kidney disease or CrCl less than 30 mL/minute (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], and ofloxacin [US]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016927\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b> Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema (&le;10%), cerebrovascular accident, hypertension, myocardial infarction, significant cardiovascular event</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (&le;10%), dizziness (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (&le;10%), skin rash (&le;10%), exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Constipation (13%), abdominal pain (&le;10%), diarrhea (&le;10%), dyspepsia (&le;10%), esophageal perforation (&le;10%), flatulence (&le;10%), gastrointestinal ulcer (&le;10%; including gastric/duodenal), heartburn (&le;10%), intestinal perforation (&le;10%), nausea (&le;10%), vomiting (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (&le;10%), hemorrhage (&le;10%), prolonged bleeding time (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased liver enzymes (&le;10%), increased serum transaminases (15%), increased serum ALT (&le;4%; &gt;8X ULN: &le;1%), increased serum AST (2% to &le;4%; &gt;8X ULN: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Infusion site reaction (10%), extravasation (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Wound healing impairment (8%), gastrointestinal inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports : Abnormal Dreams, agranulocytosis, alopecia, anaphylaxis, angioedema, anxiety, aplastic anemia, asthma, auditory impairment, blurred vision, cardiac arrhythmia, cardiac failure, change in appetite, colitis, coma, confusion, conjunctivitis, convulsions, cystitis, depression, diaphoresis, drowsiness, dyspnea, dysuria, ecchymoses, eosinophilia, eructation, erythema multiforme, esophagitis, exfoliative dermatitis, fever, fulminant hepatitis, gastritis, gastrointestinal hemorrhage, glossitis, hallucination, hematemesis, hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, hyperglycemia, hypertension, hypotension, infection, insomnia, interstitial nephritis, jaundice, leukopenia, lymphadenopathy, malaise, melena, meningitis, nervousness, oliguria, palpitations, pancreatitis, pancytopenia, paresthesia, pneumonia, polyuria, proteinuria, purpura, rectal hemorrhage, renal failure, respiratory depression, sepsis, skin photosensitivity, stomatitis, syncope, tachycardia, thrombocytopenia, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, weakness, weight changes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral:</b> Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (33%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (&le;3 x ULN; 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (4% to 8%), procedural pain (3%), dizziness (2%), falling (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (7%), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (5% to 8%), nausea (6% to 7%), diarrhea (6%), GI adverse effects (gastric ulcer, hemorrhage, and perforation; &le;4%, risk increases with therapy duration), abdominal pain (2% to 3%), vomiting (3%), dyspepsia (2% to 3%), flatulence (2% to 3%), heartburn, abdominal discomfort (2%), duodenal ulcer</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (3%), anemia, prolonged bleeding time</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (&gt;3 x ULN: &le;4%; &gt;8 x ULN: &le;1%), increased serum AST (&gt;3 x ULN; &le;4%; &gt;8 x ULN: &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Osteoarthritis (5%), arthralgia (3%), back pain (3%), limb pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (2%), renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (8%), nasopharyngitis (6%), sinusitis (3% to 5%), cough (4%), bronchitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, agranulocytosis, alopecia, anaphylactoid reaction, anaphylaxis, angioedema, anxiety, aplastic anemia, aseptic meningitis, asthma, auditory impairment, azotemia (Gurwitz, 1990), blurred vision, cardiac arrhythmia, cardiac failure, cerebrovascular accident, change in appetite, chest pain, colitis, coma, confusion, conjunctivitis, cystitis, decreased hemoglobin (Goldstein, 2011), depression, diaphoresis, diplopia, disorientation, drowsiness, dyspnea, dysuria, ecchymoses, eosinophilia, eructation, erythema multiforme, esophageal ulcer, esophagitis, exfoliative dermatitis, fever, fluid retention, fulminant hepatitis, gastritis, glossitis, hallucination, hearing loss, hematemesis, hematuria, hemolytic anemia, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, hyperglycemia, hypotension, infection, insomnia, interstitial nephritis, intestinal perforation, jaundice, leukopenia, lymphadenopathy, malaise, melena, memory impairment, meningitis, myocardial infarction, nephrotic syndrome, nervousness, oliguria, palpitations, pancreatitis, pancytopenia, paresthesia, peptic ulcer, pneumonia, polyuria, proteinuria, psychotic reaction, purpura, rectal hemorrhage, renal failure, renal papillary necrosis, respiratory depression, seizure, sepsis, skin photosensitivity, Stevens-Johnson syndrome, stomatitis, syncope, tachycardia, taste disorder, thrombocytopenia, toxic epidermal necrolysis, tremor, urticaria, vasculitis, vertigo, weakness, weight changes, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Rectal suppository</b> [Canadian product]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Also refer to adverse reactions associated with oral formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Hemorrhoids (exacerbation), local hemorrhage, proctitis, rectal irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016863\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to diclofenac (eg, anaphylactoid reactions, serious skin reactions) or bovine protein (Zipsor only) or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; use in the setting of CABG surgery; patients with moderate to severe renal impairment in the perioperative period and who are at risk for volume depletion (injection only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in U.S. labeling): Severe uncontrolled heart failure, active gastric/duodenal/peptic ulcer; active GI bleed or perforation; regional ulcer, gastritis, or ulcerative colitis; cerebrovascular bleeding or other bleeding disorders; inflammatory bowel disease; severe hepatic impairment; active hepatic disease; severe renal impairment (CrCl &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; patients &lt;16 years of age; breast-feeding; pregnancy (third trimester); recent history of bleeding or inflammatory lesions of rectum/anus (suppository only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016939\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with &quot;aspirin triad&quot; (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Contraindicated in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious (and potentially fatal) adverse cardiovascular thrombotic events, including MI and stroke. Risk may occur early during treatment and may increase with duration of use.</b> Relative risk appears to be similar in those with and without known cardiovascular disease or risk factors for cardiovascular disease; however, absolute incidence of serious cardiovascular thrombotic events (which may occur early during treatment) was higher in patients with known cardiovascular disease or risk factors and in those receiving higher doses. New onset hypertension or exacerbation of hypertension may occur (NSAIDs may also impair response to ACE inhibitors, thiazide diuretics, or loop diuretics); may contribute to cardiovascular events; monitor blood pressure; use with caution in patients with hypertension. May cause sodium and fluid retention; use with caution in patients with edema. Avoid use in heart failure (ACCF/AHA [Yancy 2013]). Avoid use in patients with recent MI unless benefits outweigh risk of cardiovascular thrombotic events. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI events: <b>[US Boxed Warning]: NSAIDs cause an increased risk of serious gastrointestinal inflammation, ulceration, bleeding, and perforation (may be fata); elderly patients and patients with history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. These events may occur at any time during therapy and without warning.</b> Avoid use in patients with active GI bleeding. In patients with a history of acute lower GI bleeding, avoid use of non-aspirin NSAIDs, especially if due to angioectasia or diverticulosis (Strate 2016). Use caution with a history of GI ulcers, concurrent therapy known to increase the risk of GI bleeding (eg, aspirin, anticoagulants and/or corticosteroids, selective serotonin reuptake inhibitors), advanced hepatic disease, coagulopathy, smoking, use of alcohol, or in elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Transaminase elevations have been reported with use; closely monitor patients with any abnormal LFT. Rare, sometimes fatal severe hepatic reactions (eg, fulminant hepatitis, hepatic necrosis, hepatic failure) have occurred with NSAID use; discontinue immediately if clinical signs or symptoms of liver disease develop or if systemic manifestations occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE inhibitors). Monitor potassium closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation (usually reversible). Patients with impaired renal function, dehydration, hypovolemia, heart failure, hepatic impairment, those taking diuretics and ACE inhibitors, and elderly patients are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Long-term NSAID use may result in renal papillary necrosis and other renal injury.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin reactions: NSAIDs may cause potentially fatal serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); may occur without warning; discontinue use at first sign of skin rash (or any other hypersensitivity).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aseptic meningitis: May increase the risk of aseptic meningitis (rarely), especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Contraindicated in patients with aspirin-sensitive asthma; severe, potentially fatal bronchospasm may occur. Use caution in patients with other forms of asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery bypass graft surgery: <b>[US Boxed Warning]: Use is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.</b> Risk of MI and stroke may be increased with use following CABG surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduced doses may be required due to extensive hepatic metabolism. Patients with advanced hepatic disease are at an increased risk of GI bleeding with NSAIDs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Avoid use in patients with advanced renal disease unless benefits are expected to outweigh risk of worsening renal function; monitor closely if therapy must be initiated. Injection is not recommended in patients with moderate to severe renal impairment and is contraindicated in patients with moderate to severe renal impairment in the perioperative period and who are at risk for volume depletion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are at greater risk for serious GI, cardiovascular, and/or renal adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Not indicated for long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: May contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Zipsor: Contains gelatin; use is contraindicated in patients with history of hypersensitivity to bovine protein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Oral solution: Indicated only for the acute treatment of migraine (not indicated for migraine prophylaxis or cluster headache). Acute migraine agents (eg, NSAIDs, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bioequivalence: Different formulations of oral diclofenac are not bioequivalent, even if the milligram strength is the same; do not interchange products.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical/dental procedures: Withhold for at least 4 to 6 half-lives prior to surgical or dental procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016932\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2E1 (weak), UGT1A6</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016933\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9103&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acemetacin: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of GI bleeding may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Angiotensin-Converting Enzyme Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Apixaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of apixaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Diclofenac (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used together with a strong CYP2C9 inhibitor.  Arthrotec (diclofenac and misoprostol) labeling specifically recommends limiting the total daily dose to a maximum of 50 mg twice/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexibuprofen: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Dexibuprofen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Drospirenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of edoxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Felbinac: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Monitor for evidence of kidney injury or decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concurrent use in CHF or cirrhosis. Concomitant use of bumetanide with indomethacin is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Nonsteroidal Anti-Inflammatory Agents may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.  Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftazone: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: Diclofenac (Systemic) may increase the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Diclofenac (Systemic) may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.  Management: Seek alternatives to the combined use of diclofenac with other nonsteroidal anti-inflammatory agents (NSAIDs).  Avoid the use of diclofenac/misoprostol with other NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pelubiprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenylbutazone: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostaglandins (Ophthalmic): Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolones. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolones. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Resveratrol: May increase the serum concentration of Diclofenac (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Rivaroxaban. Specifically, the risk of bleeding may be increased.  Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <b> Exceptions: </b>Choline Magnesium Trisalicylate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of a gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talniflumate: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Diclofenac (Systemic) may enhance the nephrotoxic effect of Tenofovir Products.  Management: Seek alternatives to this combination whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenoxicam: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide and Thiazide-Like Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolperisone: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Tolperisone. Specifically, the risk of hypersensitivity reactions may be increased. Tolperisone may enhance the therapeutic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants (Tertiary Amine): May enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Nonsteroidal Anti-Inflammatory Agents (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Diclofenac (Systemic). Management: Consider using a lower dose of diclofenac when used with voriconazole.  Arthrotec (diclofenac and misoprostol) labeling recommends limiting the total daily dose to a maximum of 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaltoprofen: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016838\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C/D (&ge;30 weeks gestation) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016839\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Diclofenac crosses the placenta. Birth defects have been observed following in utero NSAID exposure in some studies; however, data is conflicting (Bloor 2013). Nonteratogenic effects, including prenatal constriction of the ductus arteriosus, persistent pulmonary hypertension of the newborn, oligohydramnios, necrotizing enterocolitis, renal dysfunction or failure, and intracranial hemorrhage have been observed in the fetus/neonate following in utero NSAID exposure. In addition, nonclosure of the ductus arteriosus postnatally may occur and be resistant to medical management (Bermas 2014; Bloor 2013). Because they may cause premature closure of the ductus arteriosus, product labeling for diclofenac specifically states use should be avoided starting at 30-weeks gestation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use of NSAIDs can be considered for the treatment of mild rheumatoid arthritis flares in pregnant women; however, use should be minimized or avoided early and late in pregnancy (Bermas 2014; Saavedra Salinas 2015). If treatment of migraine is needed in pregnant women, agents other than diclofenac are preferred (Amundsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The chronic use of NSAIDs, including diclofenac, in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication. Consider discontinuing use in women having difficulty conceiving or those undergoing investigation of fertility. The use of NSAIDs close to conception may be associated with an increased risk of miscarriage (Bermas 2014; Bloor 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016844\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Diclofenac is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of diclofenac is 0.5% to 0.75% when calculated using the highest breast milk concentration located and compared to an infant therapeutic dose of 2 to 3 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25%, breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest milk concentration (100 mcg/L), the estimated daily infant dose via breast milk is 0.015 mg/kg/day. This milk concentration was obtained following maternal administration of oral diclofenac 150 mg/day.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, NSAIDs may be used in postpartum women who wish to breastfeed; however, agents other than diclofenac may be preferred (Amundsen 2015; Montgomery 2012) and use should be avoided in women breastfeeding infants with platelet dysfunction or thrombocytopenia (Bloor 2013; Sammaritano 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017042\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Oral immediate-release formulations may be taken with food to decrease GI distress. However, food may reduce effectiveness of oral solution and diclofenac acid (capsule). Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017046\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Monitor CBC, chemistry profile, weight gain, edema, liver function tests (baseline and periodically during chronic therapy), renal function (serum BUN, serum creatinine, urine output); occult blood loss; blood pressure; observe for bleeding, bruising; GI effects (abdominal pain, bleeding, dyspepsia); mental confusion, disorientation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016953\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8016955\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: ~50% (systemically available)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Oral: ~1.3 to 1.4 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;99%, primarily to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; undergoes first-pass metabolism; forms several metabolites (1 with weak activity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 55%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Oral: ~2 hours; ~1 hour (liquid filled capsule [Zipsor]); Injection: ~1.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: <b>Note:</b> Fasted values reported for oral products; may be delayed with food</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cambia: ~0.25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cataflam, Zorvolex: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zipsor: ~0.47 &plusmn; 0.17 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, delayed release (diclofenac sodium): 2.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet, extended release (diclofenac sodium): 5.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~65%); bile (~35%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8017266\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zipsor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $936.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zorvolex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (90): $420.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (90): $420.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Cambia Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $75.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Diclofenac Sodium ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $281.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Diclofenac Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $142.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $147.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $177.39</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Diclofenac Potassium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $275.93</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961970\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abitren (IL);</li>\n      <li>Actifen CR (PH);</li>\n      <li>Acuflam (PH);</li>\n      <li>Adiflam (ET);</li>\n      <li>Allvoran (DE);</li>\n      <li>Almiral (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Anterin (TW);</li>\n      <li>Anuva (ID);</li>\n      <li>Araclof (ID);</li>\n      <li>Arcanafenac (ZA);</li>\n      <li>Artimed (ET);</li>\n      <li>Artrites (CO);</li>\n      <li>Berifen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Betaren (IL);</li>\n      <li>Bi Su Fu (CN);</li>\n      <li>Bioran (ZW);</li>\n      <li>Catafast (SA);</li>\n      <li>Catafen (PH);</li>\n      <li>Cataflam (AE, BE, BH, CL, CY, EC, EE, EG, ET, HK, ID, IL, IQ, IR, JO, KW, LB, LK, LT, LU, LV, LY, MT, NL, NO, OM, PE, PT, QA, SA, SY, TR, TW, UY, VE, YE, ZW);</li>\n      <li>Cataflam D (ID);</li>\n      <li>Cataflam Drops (MY);</li>\n      <li>Catanac (TH);</li>\n      <li>Catas (KR);</li>\n      <li>Cencenac (TH);</li>\n      <li>Clofec (TH);</li>\n      <li>Clofen (AE, JO, KW, LB, QA, SA);</li>\n      <li>Clofen Retard (AE, KW);</li>\n      <li>Clofenex-50 (HK);</li>\n      <li>Clonac (AU);</li>\n      <li>Cordralan (PE);</li>\n      <li>Curafen (PH);</li>\n      <li>D-Fiam (TH);</li>\n      <li>Declophen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Demofenac (IL);</li>\n      <li>Depain (KR);</li>\n      <li>Diclac (CN, IE);</li>\n      <li>Diclax SR (NZ);</li>\n      <li>Dicloas (ET);</li>\n      <li>Diclobene (AT);</li>\n      <li>Diclofen (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);</li>\n      <li>Diclofen Cremogel (BH);</li>\n      <li>Diclofenac (CO);</li>\n      <li>Dicloflam (ZA);</li>\n      <li>Diclomax (IN, ZW);</li>\n      <li>Diclon (DK, MY);</li>\n      <li>Diclosan SR (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Diclosian (TH);</li>\n      <li>Diclowal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Dicofen (PH);</li>\n      <li>Difelene (VN);</li>\n      <li>Difena (TW);</li>\n      <li>Difene (IE);</li>\n      <li>Diflosid (PH);</li>\n      <li>Dioxaflex (DO, GT, HN, NI, PA, SV);</li>\n      <li>Dioxaflox (CR);</li>\n      <li>Disflam (EC);</li>\n      <li>Divoltar (ID);</li>\n      <li>Divon CR (LK);</li>\n      <li>Doflex (IN);</li>\n      <li>Dolotren (CR, DO, ES, GT, HN, NI, PA, SV);</li>\n      <li>Dolpasse (AT);</li>\n      <li>E (GR);</li>\n      <li>Ecofenac (CH);</li>\n      <li>Epifenac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Eurofenac (HK);</li>\n      <li>Fenac (AU);</li>\n      <li>Flamquit (TW);</li>\n      <li>Flector (FR, LB);</li>\n      <li>Flexagen (ZA);</li>\n      <li>Flogozan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Fortfen SR (ZA);</li>\n      <li>Imflac (AU);</li>\n      <li>Inac (SG);</li>\n      <li>Inflamac (CH);</li>\n      <li>Inflanac (HK, LK, MY, TH);</li>\n      <li>Kadiflam (ID);</li>\n      <li>Lesflam (SG);</li>\n      <li>Maxit (LK);</li>\n      <li>Merflam (ID);</li>\n      <li>Mioclof (PH);</li>\n      <li>Mobifen (BD);</li>\n      <li>Monoflam (CZ, DE);</li>\n      <li>Neodolpasse (AT);</li>\n      <li>Nepenthe (PH);</li>\n      <li>Novarin (BD);</li>\n      <li>Ofenac (KR);</li>\n      <li>Olfen (AE, BB, BM, BS, BZ, GY, HK, JM, JO, LB, MY, PR, SR, TT);</li>\n      <li>Olfen-75 SR (MY);</li>\n      <li>Osteoflam (IN);</li>\n      <li>Panamor (ZA, ZW);</li>\n      <li>Profenac (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Raost (ID);</li>\n      <li>Remafen (MY);</li>\n      <li>Remethan (DE, ET, HK, MY, SG, ZW);</li>\n      <li>Ren (HK);</li>\n      <li>Rewodina (DE, MY, RU);</li>\n      <li>Sefnac (TH);</li>\n      <li>Soproxen (TH);</li>\n      <li>Swiss Relief Dual Release (IL);</li>\n      <li>Taks (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Tromax (ET);</li>\n      <li>Ultrafen (SG);</li>\n      <li>Vartelon (HK);</li>\n      <li>Vesconac (TH);</li>\n      <li>Vivian (ZW);</li>\n      <li>Volcan (BD);</li>\n      <li>Voldic (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Voldick-K (ET);</li>\n      <li>Volna-K (TW);</li>\n      <li>Volta (TH);</li>\n      <li>Voltaflam (PK);</li>\n      <li>Voltaflex (BR);</li>\n      <li>Voltaren (AE, AR, AT, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CO, CY, CZ, DE, DK, EE, EG, ET, FI, GH, GM, GN, HK, HR, HU, ID, IL, IQ, IR, IS, IT, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, OM, PH, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Voltaren Acti-Go (IL);</li>\n      <li>Voltaren Dolo (FR);</li>\n      <li>Voltaren Rapid (AU, NZ, UA);</li>\n      <li>Voltaren SR (BH, CY, EG, HK, LB, MT, NZ, PH, SA);</li>\n      <li>Voltarene (FR, GR);</li>\n      <li>Voltarol (IE);</li>\n      <li>Voltfast (ET, SG, TH);</li>\n      <li>Voltine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Volton-CR (HK);</li>\n      <li>Voren (PH, TW);</li>\n      <li>Votalin (CN);</li>\n      <li>Votan (PH);</li>\n      <li>Votan SR (PH);</li>\n      <li>Votrex (AE);</li>\n      <li>Voveran (IN);</li>\n      <li>Vurdon (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);</li>\n      <li>Yingtaiqing (CN);</li>\n      <li>Yuren (TW);</li>\n      <li>Zobid D (LK);</li>\n      <li>Zolterol (MY);</li>\n      <li>Zolterol SR (LK, SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25776823\"></a>Amundsen S, Nordeng H, Nezvalov&aacute;-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. <i>Nat Rev Neurol</i>. 2015;11(4):209-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/25776823/pubmed\" target=\"_blank\" id=\"25776823\">25776823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"27060684\"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnold MM, McKenna F. A Double Blind Comparison of the Endoscopic and Clinical Effects of Tenoxicam and Diclofenac in Rheumatoid Arthritis. <i>Br J Rheumatol.</i> 1995;34(suppl 1):95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7704474/pubmed\" target=\"_blank\" id=\"7704474\">7704474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24663106\"></a>Bermas BL. Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy. <i>Curr Opin Rheumatol</i>. 2014;26(3):334-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/24663106/pubmed\" target=\"_blank\" id=\"24663106\">24663106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23726390\"></a>Bhala N, Emberson J, Merhi A, et al; Coxib and traditional NSAID Trialists' (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. <i>Lancet</i>. 2013;382(9894):769-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/23726390/pubmed\" target=\"_blank\" id=\"23726390\">23726390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>J Am Coll Cardiol</i>, 2008, 52(18):1502-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/19017521/pubmed\" target=\"_blank\" id=\"19017521\">19017521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23558845\"></a>Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. <i>Anesth Analg</i>. 2013;116(5):1063-1075.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/23558845/pubmed\" target=\"_blank\" id=\"23558845\">23558845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN, Heel RC, Pakes GE, et al, &ldquo;Diclofenac Sodium: A Review of Its Pharmacological Properties and Therapeutic Use in Rheumatic Diseases and Pain of Varying Origin,&rdquo; <i>Drugs</i>, 1980, 20(1):24-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6772422/pubmed\" target=\"_blank\" id=\"6772422\">6772422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo; <i>N Engl J Med</i>, 1991, 324(24):1716-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2034249/pubmed\" target=\"_blank\" id=\"2034249\">2034249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cambia (diclofenac) [prescribing information]. Newark, CA: Depomed; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cataflam (diclofenac) [prescribing information]. East Hanover, NJ: Novartis; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo; <i>Age Ageing</i>, 1984, 13(2):120-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6731166/pubmed\" target=\"_blank\" id=\"6731166\">6731166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>N Engl J Med</i>, 1984, 310(9):563-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6363936/pubmed\" target=\"_blank\" id=\"6363936\">6363936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo; <i>Hypertension</i>, 2000, 36(3):461-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/10988282/pubmed\" target=\"_blank\" id=\"10988282\">10988282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Court H and Volans GN, &ldquo;Poisoning After Overdose With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>Adverse Drug React Acute Poisoning Rev</i>, 1984, 3(1):1-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6541425/pubmed\" target=\"_blank\" id=\"6541425\">6541425</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diclofenac sodium delayed-release tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dyloject (diclofenac sodium) [prescribing information]. Lake Forest, IL: Hospira Inc; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin</i><i>Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    George S and Rahi AH, &ldquo;Thrombocytopenia Associated With Diclofenac Therapy,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(4):420-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7757871/pubmed\" target=\"_blank\" id=\"7757871\">7757871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein JL, Chan FK, Lanas A, et al. Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. <i>Aliment Pharmacol Ther</i>. 2011;34(7):808-816.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/21810115 /pubmed\" target=\"_blank\" id=\"21810115 \">21810115 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo; <i>Gastroenterology</i>, 1989, 96(2 Pt 2 Suppl):675-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2642452/pubmed\" target=\"_blank\" id=\"2642452\">2642452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo; <i>JAMA</i>, 1990, 264(4):471-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2366280/pubmed\" target=\"_blank\" id=\"2366280\">2366280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6361986\"></a>Haapasaari J, Wuolijoki E, and Ylijoki H, &ldquo;Treatment of Juvenile Rheumatoid Arthritis With Diclofenac Sodium,&rdquo; <i>Scand J Rheumatol</i>, 1983, 12(4):325-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6361986/pubmed\" target=\"_blank\" id=\"6361986\">6361986</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16204667\"></a>Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. <i>JAMA</i>. 2005;294(13):1671-1684.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/16204667/pubmed\" target=\"_blank\" id=\"16204667\">16204667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>N Engl J Med</i>, 1998, 338(11):727-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/9494149/pubmed\" target=\"_blank\" id=\"9494149\">9494149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health Canada. Summary safety review - diclofenac - risk of major heart and stroke related adverse events. http://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/diclofenac-eng.php. Published October 6, 2014. Updated October 14, 2014. Accessed September 25, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo; <i>Arch Intern Med</i>, 1998, 158(10):1108-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/9605782/pubmed\" target=\"_blank\" id=\"9605782\">9605782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Helfgott SM, Sandberg-Cook J, Zakim D, et al, &ldquo;Diclofenac-Associated Hepatotoxicity,&rdquo; <i>JAMA</i>, 1990, 264(20):2660-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2232043/pubmed\" target=\"_blank\" id=\"2232043\">2232043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo; <i>Arch Intern Med</i>, 1991, 151(7):1309-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2064481/pubmed\" target=\"_blank\" id=\"2064481\">2064481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isdale A and Wright V, &ldquo;Misoprostol/NSAID Fixed Combinations. Help or Hindrance in Clinical Practice?&rdquo; <i>Drug Saf</i>, 1995, 12(5):291-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7669258/pubmed\" target=\"_blank\" id=\"7669258\">7669258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10891521\"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo; Crit Care Med, 2002, 30(1):119-41. Available at http://www.sccm.org/pdf/sedatives.pdf. Accessed August 2, 2003.11902253</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. <i>Kidney Int</i>. 2013;3(suppl):1-150.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kulling EJ, Beckman EA, and Skagius AS, &ldquo;Renal Impairment After Acute Diclofenac, Naproxen, and Sulindac Overdoses,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1995, 33(2):173-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7897758/pubmed\" target=\"_blank\" id=\"7897758\">7897758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23215911\"></a>Montgomery A, Hale TW; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo; <i>Am J Hypertens</i>, 2000, 13(11):1161-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/11078175/pubmed\" target=\"_blank\" id=\"11078175\">11078175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo; <i>Arch Intern Med</i>, 2000, 160(6):777-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/10737277/pubmed\" target=\"_blank\" id=\"10737277\">10737277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pillans PI and O'Connor N, &ldquo;Tissue Necrosis and Necrotizing Fasciitis After Intramuscular Administration of Diclofenac,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(3):264-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7606072/pubmed\" target=\"_blank\" id=\"7606072\">7606072</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo; <i>Arch Intern Med</i>, 1993, 153(4):477-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/8435027/pubmed\" target=\"_blank\" id=\"8435027\">8435027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riad LE, Sawchuk RJ, McAlary MM, et al, &ldquo;Effect of Food on the Multiple-Peak Behavior After a Single Oral Dose of Diclofenac Sodium Slow-Release Tablet in Humans,&rdquo; <i>Am J Ther</i>, 1995, 2(4):237-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/11850655/pubmed\" target=\"_blank\" id=\"11850655\">11850655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringold S, Weiss PF, Beukelman T, et al; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Rheum</i>. 2013;65(10):2499-2512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/24092554/pubmed\" target=\"_blank\" id=\"24092554\">24092554</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson MH, Wheatley T, and Leach IH, &ldquo;Nonsteroidal Anti-inflammatory Drug-Induced Colonic Stricture; an Unusual Cause of Large Bowel Obstruction and Perforation,&rdquo; <i>Dig Dis Sci</i>, 1995, 40(2):315-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7851196/pubmed\" target=\"_blank\" id=\"7851196\">7851196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson PM and Ahmed I, &ldquo;Diclofenac and Post-tonsillectomy Haemorrhage,&rdquo; <i>Clin Otolaryngol</i>, 1994, 19(4):344-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/7994893/pubmed\" target=\"_blank\" id=\"7994893\">7994893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25776823\"></a>Saavedra Salinas M&Aacute;, Barrera Cruz A, Cabral Casta&ntilde;eda AR, et al. Clinical practice guidelines for the management of pregnancy in women with autoimmune rheumatic diseases of the Mexican College of Rheumatology. Part II. <i>Reumatol Clin</i>. 2015;11(5):305-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/25776823/pubmed\" target=\"_blank\" id=\"25776823\">25776823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24614280\"></a>Sammaritano LR, Bermas BL. Rheumatoid arthritis medications and lactation. <i>Curr Opin Rheumatol</i>. 2014;26(3):354-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/24614280/pubmed\" target=\"_blank\" id=\"24614280\">24614280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smolinske SC, Hall AH, Vandenberg SA, et al, &ldquo;Toxic Effects of Nonsteroid Anti-inflammatory Drugs in Overdose. An Overview of Recent Evidence on Clinical Effects and Dose-Response Relationships,&rdquo; <i>Drug Saf</i>, 1990, 5(4):252-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2198051/pubmed\" target=\"_blank\" id=\"2198051\">2198051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2016;111(4):459-474. doi: 10.1038/ajg.2016.41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/26925883/pubmed\" target=\"_blank\" id=\"26925883\">26925883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vale JA and Meredith TJ, &ldquo;Acute Poisoning Due to Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>Med Toxicol</i>, 1986, 1(1):12-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/3537613/pubmed\" target=\"_blank\" id=\"3537613\">3537613</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1990, 19(1):44-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/2199127/pubmed\" target=\"_blank\" id=\"2199127\">2199127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren Rapide (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren SR (diclofenac) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voltaren-XR extended-release tablets (diclofenac) [prescribing information]. East Hanover, NJ: Novartis; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wafin F, Valindas E, and Wuolijoki E, &ldquo;Comparison of Diclofenac and Indomethacin Suppositories in Rheumatoid Arthritis,&rdquo; <i>Clin Rheumatol</i>, 1984, 3(1):67-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/6380897/pubmed\" target=\"_blank\" id=\"6380897\">6380897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willkens RF, &ldquo;Worldwide Clinical Safety Experience With Diclofenac,&rdquo; <i>Semin Arthritis Rheum</i>, 1985, 15(2 Suppl 1):105-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/3909410/pubmed\" target=\"_blank\" id=\"3909410\">3909410</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo; <i>N Engl J Med</i>, 1998, 338(11):719-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diclofenac-systemic-drug-information/abstract-text/9494148/pubmed\" target=\"_blank\" id=\"9494148\">9494148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipsor (diclofenac) [prescribing information]. Newark, CA: Depomed Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zorvolex (diclofenac) [prescribing information]. Philadelphia, PA: Iroko Pharmaceuticals; May 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9103 Version 261.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8016815\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8016831\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8016832\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8017469\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8017009\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F26620531\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8017010\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8017011\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8017012\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8017239\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8016834\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F11590267\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8016830\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8017044\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8016835\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725523\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8016829\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8016927\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8016863\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8016939\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8016932\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8016933\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8016838\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8016839\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8016844\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8017042\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8017046\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8016953\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8016955\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8017266\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961970\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9103|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diclofenac-systemic-patient-drug-information\" class=\"drug drug_patient\">Diclofenac (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=diclofenac-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Diclofenac (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}